Review of association between high-dose tigecycline and clinical outcome
10.13699/j.cnki.1001-6821.2018.03.053
- VernacularTitle:替加环素超剂量使用与临床结局相关性的评价
- Author:
Shu-Yao LIANG
1
;
Chen-Xiao WANG
;
Wei LIU
;
Suo-Di ZHAI
Author Information
1. 北京大学第三医院药剂科
- Keywords:
tigecycline;
high dosage;
safety;
efficacy;
systematic review
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):362-364
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of the usage of high-dose tigecycline.Methods Databases including PubMed,EmBase,The Cochrane Library,CNKI,Wanfang data and Clinical Tirals.gov were searched to select randomized controlled trials (RCTs) and observational studies that met the inclusion criteria from inception to May 2017.Two reviewers independently screened literature,extracted data,and evaluated the risk of bias of included studies.Risk ratio and 95％ confidence interval were used to present results.Meta-analysis was performed using RevMan 5.3 software to analyze patients' all-cause mortality,micro-biological clearance rate,clinical effective rate and clinical cure rate.Result A total of 5 observational studies were included,which involved 348 patients.The results of meta-analysis indicated that compared with the regular-dose group(50 mg,q12 h),the high-dose group(＞50 mg,q12 h) could significantly decrease all-cause mortality (RR =0.65,95％ CI =0.50-0.84,P ＜ 0.01),increase micro-biological clearance rate(RR =1.71,95％ CI =1.22-2.41,P ＜ 0.01),clinical effective rate (RR =1.46,95％ CI =1.13-1.87,P ＜ 0.01) and clinical cure rate (RR =1.71,95％ CI =1.71-2.48,P ＜ 0.01).Conclusion Compared with regular-dose tigecycline (50 mg,q12 h),the usage of high-dose tigecycline (＞ 50 mg,q12 h) showed superiority.
